Zachary Epstein-Peterson, MD
Lymphoma Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- All non-Hodgkin and Hodgkin Lymphomas, with a focus on T-Cell Lymphomas
- Cutaneous (Skin) Lymphomas
- and Mantle Cell Lymphoma
About Me
- Attending Physician
I am a hematologist-oncologist who works with a multidisciplinary group of physicians, advanced practice providers, nurses, pharmacists, administrative staff, and other healthcare professionals devoted to caring for patients at Memorial Sloan Kettering Cancer Center who are facing a diagnosis of lymphoma. Having completed much of my medical training at MSK, I know the exceptional, individualized care that we provide to each patient, and I am proud to provide patient care as part of our Lymphoma Service.
Read more
Since I made the choice to pursue a career in medicine, I have been drawn to the intense bond forged between oncologists and their patients. My care philosophy centers around creating the conditions in which patients feel comfortable to develop that bond with me as we embark on a care journey together. I recognize that a diagnosis of cancer is unsettling, and my goal in meeting each new patient and their caregivers is to truly understand their perspective and to ally with them. For some patients, a lymphoma diagnosis may require a “watch and wait” approach; for others, more intensive treatments may be needed. I give each patient the time, attention, and thoroughness that they deserve at each visit. I also prioritize personalized care that allows my patients to feel well cared for from physical and emotional/spiritual perspectives.
Although many advancements have been made in treating lymphomas, there is still significant progress to be made, and I am thankful to be at the forefront of defining new treatment avenues here at MSK. My research focuses on helping to develop newer treatments, particularly for T-cell and cutaneous lymphomas — an especially challenging subset within non-Hodgkin lymphomas. My other research interests include mantle cell lymphoma and viral/immunodeficiency-related lymphomas. Besides clinical trials investigating promising new therapies, I also participate in translational research with outstanding laboratory and computational colleagues seeking to understand why current treatments don’t always work for each patient. Ultimately, our hope is that this will uncover new vulnerabilities that we can target with different treatment approaches. Outside of work, I am passionate about vegetarianism, classical music, and travel.
A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.
My Specialties
- All non-Hodgkin and Hodgkin Lymphomas, with a focus on T-Cell Lymphomas
- Cutaneous (Skin) Lymphomas
- and Mantle Cell Lymphoma
Education
- MD, Harvard Medical School
Residencies
- Internal Medicine - University of Washington
- Internal Medicine - NewYork-Presbyterian Cornell Medical Center
- Internal Medicine (Chief Resident) - Memorial Sloan Kettering Cancer Center
Awards and Honors
- ASCO-AACR Methods in Clinical Research Workshop Participant (2020)
- AACR-AstraZeneca Lymphoma Research Fellowship (2020-2022)
- Lymphoma Research Foundation, Lymphoma Scientific Research Mentoring Program (2021-2023)
- AIDS Malignancy Consortium Scholar Program (2021-2022)
- Lacher Fellowship, Memorial Sloan Kettering Cancer Center (2019-2021)
- Lymphoma Research Foundation, Mantle Cell Lymphoma Scientific Workshop, Michael E. Williams MD Abstract Achievement Award (2021)
Fellowships
- Hematology and Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Epstein-Peterson sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Epstein-Peterson
- A Phase I Study of KT-333 in People with Lymphoma and Large Granular Lymphocytic Leukemia
- Clinical Trials Co-Investigated by Dr. Epstein-Peterson
- A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
- AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Zachary Epstein-Peterson discloses the following relationships and financial interests:
-
GenMab
Professional Services and Activities -
OncLive
Professional Services and Activities
-
WebMD
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].